Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Ofev 150mg Capsules: Pioneering Treatment for Lung Diseases
Introduction:
Ofev 150mg Capsules, containing the active ingredient nintedanib, heralds a new era in the treatment of certain debilitating lung diseases. As a tyrosine kinase inhibitor, Ofev offers therapeutic promise in conditions such as idiopathic pulmonary fibrosis (IPF) and systemic sclerosis-associated interstitial lung disease (SSc-ILD).
Key Information:
Type of Medication: Tyrosine Kinase Inhibitor
Active Ingredient: Nintedanib
Indications: Idiopathic Pulmonary Fibrosis (IPF), Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Mechanism of Action of Ofev 150mg Capsules:
Ofev 150mg Capsules exert their therapeutic effects by inhibiting multiple receptor tyrosine kinases crucial for fibrosis and inflammation processes in the lungs. By targeting fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR), and vascular endothelial growth factor receptor (VEGFR), Ofev mitigates fibrosis progression and reduces inflammation, thereby preserving lung function.
Uses of Ofev 150mg Capsules:
Idiopathic Pulmonary Fibrosis (IPF): Ofev 150mg Capsules are indicated for the treatment of IPF, a chronic lung condition characterized by progressive scarring of lung tissue, leading to impaired lung function and respiratory symptoms.
Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Ofev 150mg Capsules are also prescribed for SSc-ILD, a lung disease associated with systemic sclerosis, where lung fibrosis significantly impacts respiratory function and quality of life.
Benefits of Ofev 150mg Capsules:
Slows Disease Progression: Ofev 150mg Capsules have demonstrated efficacy in slowing the decline of lung function in patients with both IPF and SSc-ILD. By reducing the rate of decline, Ofev enhances patient quality of life and extends survival.
Reduces Acute Exacerbations: Ofev 150mg Capsules have been shown to decrease the frequency and severity of acute exacerbations in IPF patients, mitigating the risk of life-threatening complications.
Improves Exercise Capacity: Studies indicate that Ofev 150mg Capsules can enhance exercise tolerance in IPF patients, enabling them to engage in daily activities with greater ease and comfort.
Beside this well also export in other countries